Selank
Selank is a seven–amino-acid peptide that combines anxiety relief and cognitive support by balancing key brain chemicals. It works by balancing neurotransmitters like serotonin and dopamine, while also increasing brain-derived neurotrophic factor (BDNF) to support learning and memory. In research studies, Selank has reduced stress levels without causing drowsiness and improved attention and information processing, making it a versatile tool in cognitive and mood-related investigations.
Compound Overview
About the product
The sequence of Selank is Thr–Lys–Pro–Arg–Pro–Arg–Arg, with an additional N-terminal acetyl group to improve stability. It contains only natural L-amino acids and no non-natural modifications beyond acetylation. Selank is synthesized by Fmoc solid-phase peptide methods and purified by HPLC to ≥95 % purity. Mass spectrometry confirms its correct sequence and acetylation.
Selank modulates levels of key neurotransmitters, such as increasing serotonin and dopamine turnover, without directly binding to their receptors. It also regulates the expression of brain-derived neurotrophic factor (BDNF), supporting neuronal health and plasticity. Additionally, it exhibits immunomodulatory effects by balancing cytokine production. These combined actions contribute to reduced anxiety and improved cognitive processing.
Selank is studied primarily for its fast-acting anxiolytic (anti-anxiety) and nootropic (cognitive-enhancing) effects. In clinical trials, single intranasal doses reduced anxiety scores within hours and maintained effects for days. Patients also showed improved attention and memory performance on standardized tests. Its dual neural and immune modulation makes it a candidate for stress-related cognitive disorders.
Reported adverse events are minimal and include occasional mild nasal irritation with intranasal delivery. No significant changes in vital signs or laboratory parameters have been observed in studies lasting up to four weeks. Selank does not cause sedation or withdrawal symptoms. Safety in pregnancy, lactation, and long-term use beyond study periods remains unestablished.
Selank is produced by Fmoc solid-phase peptide synthesis, sequentially coupling seven amino acids on a resin support. After chain assembly and N-terminal acetylation, it is cleaved and purified by preparative HPLC to research-grade purity. Analytical HPLC and mass spectrometry verify sequence integrity and purity. Manufacturing follows peptide-compounding standards under good laboratory practice.
Selank is approved for medical use in Russia and some neighboring countries as an anxiolytic and cognitive enhancer. It is not approved by the U.S. FDA, EMA, or other major Western regulators. Outside approved regions, it is available only for research under investigational-new-drug or equivalent protocols. No over-the-counter or prescription products exist in most countries.
Clinical studies have used 0.15–0.3 mg Selank intranasally one to three times daily for up to four weeks. Single-dose protocols often employ 0.3 mg for rapid anxiolysis. No standardized dosing guidelines exist outside these studies. All administration should follow approved investigational protocols.
Do administer intranasally to ensure rapid central nervous system delivery.Do monitor anxiety scales and cognitive performance during use.Don’t exceed three doses per day without medical oversight.Don’t use during pregnancy, lactation, or in patients with uncontrolled psychiatric disorders.
Q: How quickly does Selank work?A: Anxiety reduction can be observed within 1–3 hours of a single dose.Q: Does it cause drowsiness?A: No; Selank does not induce sedation.Q: Can it be taken long term?A: Studies up to four weeks show safety, but longer-term data are not available.
For research use only. Not approved for medical use.
